Formatech, through its Fillanthropy Program, will formulate and fill ViroMed’s VM206 vaccine targeting breast cancer. Formatech will donate the services required to aseptically fill and finish one lot of the vaccine to support ViroMed’s upcoming clinical trials. Formatech plans to complete the production run in March 2010.

“We’re excited to have the opportunity to work with ViroMed on this program,” said Jeffrey Bernard, Formatech’s director of business development. “VM206 is a plasmid DNA vaccine that targets HER2/neu positive breast cancer. Animal studies have demonstrated the vaccine’s ability to eliminate tumors and to prevent relapse and metastases. We are hopeful and optimistic that VM206 will prove to be effective in human trials.”

“We would like to thank Formatech and the Fillanthropy Program for choosing to support ViroMed’s development of VM206,” said Dr. Sunyoung Kim, co-chief executive officer of ViroMed. “We believe that our goal to develop medicines for diseases for which there are no current effective treatments is in line with the program’s mission of helping to make new drugs available as soon as possible.”